Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD1 | Q15139 | 17/20 | 0.57 |
| ▸ | PRKD2 | Q9BZL6 | 13/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7957162 | 0.92 | PRKD1 (0.68) | PRKD1PRKD2ADRB1SYKTBK1 | |
| SCHEMBL1579532 | 0.89 | PRKD1 (0.61) | PRKD1PRKD2ADRB1 | |
| SCHEMBL7946234 | 0.89 | PRKD1 (0.60) | PRKD1PRKD2ADRB1SYK | |
| SCHEMBL12723496 | 0.89 | PRKD1 (0.58) | PRKD1PRKD2ADRB1SYKTBK1 | |
| SCHEMBL1592600 | 0.89 | PRKD1 (0.58) | PRKD1PRKD2ADRB1SYKTBK1 | |
| SCHEMBL1580416 | 0.87 | PRKD1 (0.56) | PRKD1PRKD2ADRB1SYKTBK1 | |
| SCHEMBL1592040 | 0.87 | PRKD1 (0.63) | PRKD1PRKD2ADRB1SYKTBK1 | |
| SCHEMBL12701013 | 0.87 | PRKD1 (0.56) | PRKD1PRKD2ADRB1SYKTBK1 | |
| SCHEMBL1579731 | 0.87 | PRKD1 (0.56) | PRKD1PRKD2ADRB1SYKTBK1 | |
| SCHEMBL1580476 | 0.87 | PRKD1 (0.76) | PRKD1PRKD2ADRB1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092505-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092505-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092505-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092505-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | PRKD1 4750/4885PRKD2 4659/4885ADRB1 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.